drugset / Trial / NCT05187208
PARP Inhibitor Oral Maintenance in Low-Risk Ovarian Cancer
Phase 4
Unknown
102 enrolled
Seoul National University Hospital
Asan Medical Center · collabSamsung Medical Center · collabTakeda · collabYonsei University · collab
NaSingle-groupOpen-labelTreatment
Summary
This study is the phase IV, open-label, clinical trial to determine the efficacy of niraparib maintenance therapy in BRCA1/2 wild-type, advanced-stage, low-risk, primary ovarian cancer patients.
Timeline
- Start
- 2022-01
- Primary completion
- 2025-12
- Completion
- 2025-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Niraparib | Small molecule | 200 mg | — |
| Subject | Niraparib | Small molecule | 300 mg | — |